The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Investing.com -- CRISPR Therapeutics (NASDAQ: CRSP) reported a wider-than-expected loss for the second quarter of 2025, sending shares down 6.1% as both earnings and revenue fell significantly short ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended ...

Precision BioSciences Inc., a clinical-stage company developing gene editing therapies for diseases with high unmet need, has ...

Sickle cell disease is an inherited blood disorder that primarily affects Black and Hispanic people. There are significant ...

Visits to the emergency department were associated with higher parental adverse childhood experience scores and lower resiliency in parents of children with sickle cell disease.

Daniel Cressy yawned, tired after three days of watching a machine pull blood out of his body, extract his stem cells and ...

Martin Mwita, 21, stands for a portrait in Bellevue on Saturday, Aug. 2, 2025. Mwita, became one of a handful of people ...

Sentara’s ongoing partnership with ODU and Macon & Joan Brock Virginia Health Sciences is helping shape a healthier future ...

If successful, the access model for sickle cell disease gene therapies could serve as a blueprint for other such treatments ...